Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.1 BRL | +88.53% | +64.58% | +195.85% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Sales 2022 | 105M 20.21M | Sales 2023 | 118M 22.76M | Capitalization | 470M 90.47M |
---|---|---|---|---|---|
Net income 2022 | -92M -17.71M | Net income 2023 | -81M -15.6M | EV / Sales 2022 | 5.9 x |
Net Debt 2022 | 67.72M 13.04M | Net Debt 2023 | 125M 24.05M | EV / Sales 2023 | 5.03 x |
P/E ratio 2022 |
-5.37
x | P/E ratio 2023 |
-5.93
x | Employees | 130 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.26% |
1 day | +88.53% | ||
1 week | +64.58% | ||
Current month | +67.65% | ||
1 month | +85.27% | ||
3 months | +212.04% | ||
6 months | +312.05% | ||
Current year | +195.85% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Director of Finance/CFO | - | 19-04-15 | |
Luciano Vilela
CTO | Chief Tech/Sci/R&D Officer | - | 14-02-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 14-01-31 | |
Director/Board Member | 84 | 15-10-12 | |
Director/Board Member | 81 | 13-12-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 17.1 | +5.43% | 473,300 |
24-04-18 | 16.22 | +5.67% | 410,800 |
24-04-17 | 15.35 | +38.16% | 368,500 |
24-04-16 | 11.11 | -1.24% | 19,800 |
24-04-15 | 11.25 | +8.28% | 226,600 |
Delayed Quote Sao Paulo, April 19, 2024 at 04:07 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+195.85% | 293M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- BIOM3 Stock